Andere Kunden interessierten sich auch für
![MiR-615-5p e miR-155-5p na Imunoterapia do Carcinoma Hepatocelular:]( "MiR-615-5p e miR-155-5p na Imunoterapia do Carcinoma Hepatocelular:")
MiR-615-5p e miR-155-5p na Imunoterapia do Carcinoma Hepatocelular:24,99 €![MiR-615-5p y miR-155-5p en la inmunoterapia del carcinoma hepatocelular:]( "MiR-615-5p y miR-155-5p en la inmunoterapia del carcinoma hepatocelular:")
MiR-615-5p y miR-155-5p en la inmunoterapia del carcinoma hepatocelular:24,99 €![MiR-615-5p e miR-155-5p nell'immunoterapia del carcinoma epatocellulare:]( "MiR-615-5p e miR-155-5p nell'immunoterapia del carcinoma epatocellulare:")
MiR-615-5p e miR-155-5p nell'immunoterapia del carcinoma epatocellulare:24,99 €![MiR-615-5p et miR-155-5p dans l'immunothérapie du carcinome hépatocellulaire:]( "MiR-615-5p et miR-155-5p dans l'immunothérapie du carcinome hépatocellulaire:")
MiR-615-5p et miR-155-5p dans l'immunothérapie du carcinome hépatocellulaire:24,99 €![MiR-615-5p und miR-155-5p in der Immuntherapie des hepatozellulären Karzinoms:]( "MiR-615-5p und miR-155-5p in der Immuntherapie des hepatozellulären Karzinoms:")
MiR-615-5p und miR-155-5p in der Immuntherapie des hepatozellulären Karzinoms:36,90 €![MiR-615-5p i miR-155-5p w immunoterapii gepatocellülqrnoj karcinomy:]( "MiR-615-5p i miR-155-5p w immunoterapii gepatocellülqrnoj karcinomy:")
MiR-615-5p i miR-155-5p w immunoterapii gepatocellülqrnoj karcinomy:24,99 €![miR-486-5p and Liver Cancer Therapy: A Beautiful Mind Act]( "miR-486-5p and Liver Cancer Therapy: A Beautiful Mind Act")
miR-486-5p and Liver Cancer Therapy: A Beautiful Mind Act41,99 €
Stemming the rising tide of global ill health from liver disorders, hepatologists worldwide have never been challenged as such. Hepatocellular carcinoma (HCC) poses a heavy burden globally, pivoting on the geographic region, in Egypt; HCC ranks the second most prevalent cancer and the second most frequent cause of cancer related mortality. Yet, compelling the need to understand the pathogenesis of HCC. Despite being considered a main target in efforts directed towards drug development for HCC, the driving motto in the pathogenesis of HCC, IGF/IGF-IR pathway, has recently been cast in the homeostatic regulation of immunity. Provokingly, in my master thesis, I focused on immunotherapy utilizing NK cells to provide new insights in eradicating HCC and reconcile the challenge. Accordingly, miR-615-5p and miR-155 were chosen for such trial, paving the road for correction of NK functional impairment ex-vivo through IGF-axis manipulation and future perfusion of the cytotoxic NKs to HCC patients . Part of this work was presented in the Liver Meeting (AASLD), San Francisco 2015 and in the EASL international liver Congress Vienna 2015 and ranked from the top 10% e-posters in the convention.